Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M130,697Revenue $M37,075Net Margin (%)12.3Altman Z-Score2.5
Enterprise Value $M140,590EPS $1.8Operating Margin %17.4Piotroski F-Score6
P/E(ttm)27.1Beneish M-Score-2.4Pre-tax Margin (%)16.1Higher ROA y-yY
Price/Book2.110-y EBITDA Growth Rate %2.6Quick Ratio1.3Cash flow > EarningsN
Price/Sales3.55-y EBITDA Growth Rate %-2.5Current Ratio1.8Lower Leverage y-yN
Price/Free Cash Flow62.9y-y EBITDA Growth Rate %7.5ROA % (ttm)9.1Higher Current Ratio y-yY
Dividend Yield %3.3PEG--ROE % (ttm)15.8Less Shares Outstanding y-yN
Payout Ratio %84.0Shares Outstanding M2,639ROIC % (ttm)15.6Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYNWQ Managers 2015-03-31 Add0.61%$44 - $51.12
($47.81)
$ 49.473%Add 33.50%3,927,517
SNYJames Barrow 2015-03-31 Reduce-0.04%$44 - $51.12
($47.81)
$ 49.473%Reduce 1.88%30,225,221
SNYHOTCHKIS & WILEY 2015-03-31 Add0.02%$44 - $51.12
($47.81)
$ 49.473%Add 0.77%11,782,180
SNYThird Avenue Management 2015-03-31 Sold Out -0.012%$44 - $51.12
($47.81)
$ 49.473%Sold Out0
SNYDodge & Cox 2015-03-31 Reduce-0.01%$44 - $51.12
($47.81)
$ 49.473%Reduce 0.55%43,034,073
SNYFirst Eagle Investment 2015-03-31 Sold Out -0.0038%$44 - $51.12
($47.81)
$ 49.473%Sold Out0
SNYKen Fisher 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 49.473%Reduce 0.21%13,058,095
SNYMario Gabelli 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 49.473%Reduce 9.53%4,700
SNYCharles Brandes 2015-03-31 Add$44 - $51.12
($47.81)
$ 49.473%Add 0.08%2,573,969
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 49.472%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 49.472%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 49.472%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 49.472%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 49.472%New holding1,102
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 49.47-8%Add 14.55%5,670,000
SNYFirst Eagle Investment 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 49.47-8%Reduce 94.39%34,157
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 49.47-7%Reduce 52.34%2,602,503
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 49.47-7%Add 90.38%4,950,000
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 49.47-2%New holding2,600,000
SNYHOTCHKIS & WILEY 2014-03-31 Add0.75%$47.77 - $53.63
($50.68)
$ 49.47-2%Add 65.83%9,804,594
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-47.93view
Sanofi10% Owner 2015-01-26Buy647,448$95-47.93view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-46.9view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-26.03view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67544.98view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
    Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
    Mt Stocks Apr 19 2015 
    Scottrade Mar 22 2015 
    Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
    Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
    FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
    Dodge & Cox 2014 Equity Year in Review Feb 19 2015 

    More From Other Websites
    Sanofi's New Basal Insulin Lantus® XR, Known as Toujeo® in the U.S. and Europe, Approved in Japan... Jul 03 2015
    Never mind Greece, Europe will beat the U.S.: Strategist Jul 02 2015
    Sanofi Signs a Global Agreement with SUEZ environnement To Enhance Water and Waste Management Jul 02 2015
    Analysts Battle Over MannKind -- but Who's Right? Jul 01 2015
    The Zacks Analyst Blog Highlights: Delhaize Group, Sanofi and Luxfer Holdings - Press Releases Jul 01 2015
    MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin Jun 30 2015
    Roche 'High Efficacy' MS Drug Succeeds In Trials Jun 30 2015
    Is Grexit Inevitable? 3 Stocks to Buy - Analyst Blog Jun 30 2015
    New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol Jun 30 2015
    New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol Jun 30 2015
    3 European Stocks Paying Juicy Dividends Jun 29 2015
    New Sanofi CEO to unveil five-year plan in November - unions Jun 26 2015
    New Sanofi CEO to unveil five-year plan in November -unions Jun 26 2015
    Pep Boys, Acacia Research, Sanofi, Unilever and Continental Aktiengesellschaft highlighted as Zacks... Jun 24 2015
    Viehbacher to head $2bn Bertarelli healthcare fund Jun 23 2015
    Greece Deal Likely? 3 Stock Picks - Analyst Blog Jun 23 2015
    Former Sanofi CEO Makes Science Comeback With Bertarelli Fund Jun 23 2015
    Top Europe Stocks Rally On Greece Bailout Hopes Jun 22 2015
    Biotechs about to break out: Pro Jun 19 2015
    Sanofi Starts Dosing in Phase I/II Study on Olipudase Alfa - Analyst Blog Jun 16 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK